- Clinical Trials
- April 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- January 2024
- 395 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Drug Pipelines
- February 2022
- 60 Pages
Global
From €9096EUR$9,995USD£7,798GBP
- Report
- November 2023
- 381 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- March 2024
- 90 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- October 2024
Global
From €3185EUR$3,500USD£2,731GBP
- Report
- September 2021
Global
From €4414EUR$4,850USD£3,784GBP
- Book
- July 2009
- 1116 Pages
Carbamazepine is a drug used to treat epilepsy and other neurological disorders. It is classified as an anticonvulsant and is used to treat seizures, trigeminal neuralgia, and bipolar disorder. It works by decreasing the activity of certain nerve cells in the brain, which helps to reduce the frequency and severity of seizures. It is also used to treat certain types of pain, such as trigeminal neuralgia. Carbamazepine is a member of the Central Nervous System (CNS) drug class, which includes drugs used to treat neurological disorders.
Carbamazepine is available in both generic and brand-name forms. It is available in tablet, capsule, and liquid forms, and is usually taken twice a day. The dosage and duration of treatment depend on the condition being treated. Common side effects of carbamazepine include dizziness, drowsiness, nausea, and vomiting.
Some companies in the Carbamazepine market include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more